


## Novel 13-Berberine derivatives as EPIs for MexXY system in *Pseudomonas aeruginosa* strains

Giorgia Giorgini

Molecular Modeling Laboratory Prof.ssa Galeazzi Roberta




```

PA14 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000
    
```

### Background:


*Pseudomonas aeruginosa* is an opportunistic pathogen responsible of lifethreatening infections among immunocompromised patients and it is the principal cause of respiratory infections in cystic fibrosis (CF) patients<sup>1</sup>. MexXY-OprM is the main RND (resistance nodulation division family) efflux pump system due to of the aminoglycoside extrusion (i.e. Tobramycin)<sup>2</sup>.

**AIMS:** A possible strategy is hindering the efflux pump mechanism through efflux pump inhibitors (EPIs) in a combined antibiotic/EPIs therapy.<sup>3</sup> In this study, an *in silico/in vitro* evaluation of the stability and efficacy of three synthetic 13-Berberine derivatives in complex with MexY polymorphic proteins has been carried out, considering three different *P. aeruginosa* strains (PAO1,PA7,PA14)



1) Berberine 2) 13-(2-methylbenzyl)berberine 3) 13-(4-methylbenzyl)berberine

4) 13-(4-trifluoromethylbenzyl)berberine



### Molecular docking:

Autodock 4.2.6 Lamarckian Genetic Algorithm. Grid box 50x50x50(Å<sup>3</sup>)

### Molecular dynamics:

homotrimeric system in POPC bilayer, TIP3P water model used for solvation, NaCl 0.15M physiological condition. Equilibration steps using NVT and NPT ensembles, production phase in NPT using T-coupling Noose-Hoover and Pressure coupling Berendsen barostat (NPT ensemble) T=300K, 1bar. CHARMM36 force field. LINCS algorithm for constraints.

MexY-PA7-EPIs Molecular Docking

MexY-PAO1-EPIs Molecular Docking


MexY-PA14-EPIs Molecular Docking

Violet= 13-2-methylbenzylberberine green= 13-4-methylbenzylberberine cyan= 13-4-trifluoromethylbenzylberberine

### Free Gibbs energy of binding kJ/mol



### MIC+EPI μg/mL





### First computational step

- ✓ Sequences multi-alignment highlighting mutations.
- ✓ Comparison of different ligands poses within inhibition site pocket.
- ✓ Analysis of molecular interactions.
- ✓ Molecular dynamic simulations of macromolecular systems, assessing the ligands' stability within pockets

### Second step: *in silico/in vitro* analysis

- ✓ *In vitro* microbiological testing
- ✓ ΔG calculations with MM/PBSA method
- ✓ Analysis of RMSF for pocket's residues
- ✓ Analysis of interacting residues along the MD trajectories.
- ✓ Comparison of MexY PA7 and PAO1 complexes with 13-(2-CH<sub>3</sub>benzyl)berberine

### ADME/TOX PREDICTION



Giorgini, G.; Mangiaterra, G.; Cedraro, N.; Laudadio, E.; Sabbatini, G.; Cantarini, M.; Minelli, C.; Mobbili, G.; Frangipani, E.; Biavasco, F.; Galeazzi, R. Berberine Derivatives as *Pseudomonas aeruginosa* MexXY-OprM Inhibitors: Activity and *In Silico* Insights. *Molecules* **2021**, *26*, 6644. <https://doi.org/10.3390/molecules2621664>

**Conclusion:** PA7 MexY protein presents a huge number of residues mutations within the inhibition site with respect to the PAO1 one that influence the ligand's electrostatic and steric complementarity guiding interactions; thus is useful to consider such variations for choosing the best substituent in function of the aminoacidic composition. RMSF and the entity of interactions during the simulation time evidence both quantitatively and qualitatively the best stability of the orto-methyl-benzyl derivative. For this compound, within the MexY complex in PA7 strain there are efficacious interactions more than in PAO1, evidencing the influence of aminoacidic pocket. The substituent according to its stereoelectronic properties and steric hindrance results in high stability *in silico* and besides confirms the best synergic activity with Tobramycin in the microbiological *in vitro* testing.

### References:

- 1)M.F.Moradali et al.(2017), *Fcimb*, Vol7,39. 2)D.Dey et al.(2020), *Aac.asm*, Vol64,8 3)M.AIMatar et al.(2020), *Pharmacol Rep.* 73(1):1-16. 4)A.Waterhouse et al.(2018), *Nucleic Acids Res*, 46:W296-W303. 5)K.Katoh et al.(2019), *Briefings in Bioinformatics*, Vol20,4,1160-1166. 6)G.M.Morris et al.(2009), *J Comput Chem.* 30(16):2785-2791. 7)E.Laudadio et al.(2019), *Journal of Natural Products*, 82(7), pp. 1935-1944 8)G.Mangiaterra et al.(2021), *J.Nat.Prod.* 84, 993-1001. 9)M.J.Abraham(2015), *SoftwareX*, Vol1-2,pp.91 10)P.Ruggerone et al.(2013) *Curr Top Med Chem.* 13(24):3079-100 11)I.Alav et al.(2021), *Chem.Rev.* Vol.121,pp.5479-5596